EUVIMEDEUVIMED entdecken
Crossref

Inhibiting VEGFC - mediated hepatocyte - macrophage regulatory axis contributes to protective effects of naringin against high - fat diet - induced hepatic fibrosis

Jingya Li, Ao Nie, Xinyi Li, Zheng Chen, Kai Xu, Junbin Yan, Kannan Yao, Xiaojie Lin, Wei Mao, Zhiyun Chen, Wei Hong

Phytomedicine · 2026

DOI: 10.1016/j.phymed.2025.157682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026. Verfasst von Jingya Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, China. Hauptthemen laut MEDLINE: Flavanones, Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, Hepatocytes. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Zhejiang Chinese Medical University, National Natural Science Foundation of China, Basic Public Welfare Research Program of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Naringin (NAR) has shown anti-fibrotic effects. This study found it alleviates non-alcoholic steatohepatitis (NASH)-associated liver fibrosis and downregulates vascular endothelial growth factor C (VEGFC). However, the pathophysiological role of VEGFC in NASH and its contribution to NAR's protection remain unclear. OBJECTIVE: To determine whether and how the downregulation of VEGFC contributes to the protective effect of NAR against NASH-associated hepatic fibrosis. METHODS: A mouse model of NASH fibrosis was induced by a 24-week high-fat diet (HFD). Mice were treated concomitantly with NAR-L (25 mg/kg/day), NAR-H (50 mg/kg/day), or SAR131675 (SAR, 30 mg/kg/day) from week 9 to 24 (16 weeks). Clinical serum VEGFC levels were measured in a hospital cohort (n = 165); human hepatic VEGFC expression was analyzed in using data from Gene Expression Omnibus (GEO) datasets (GSE162694, GSE130970). Hepatocyte-specific Vegfc knockout mice (VegfcHep‑cKO) were generated by crossing Vegfcflox/flox with Alb-CreERT2 (Albumin-CreERT2) mice. In vitro, AML12 hepatocytes were pretreated (oleic acid, recombinant VEGFC, or Vegfc genetic modulation); these cells or their conditioned medium were used to stimulate bone marrow-derived macrophages to assess macrophage migration and phenotypic switching. RESULTS: NAR and SAR131675 ameliorated liver inflammation and fibrosis in mice, downregulated VEGFC and CCL2/CCR2, reduced Ly6Chigh monocyte infiltration, and promoted Ly6Chigh-to-Ly6Clow macrophage phenotypic switch. Clinical data showed elevated VEGFC in NAFLD and NASH patients. VegfcHep‑cKO mice exhibited similar therapeutic effects. In vitro, hepatocyte-derived VEGFC promoted macrophage migration via VEGFR3 and CCL2/CCR2; inhibited phenotypic transition via regulating IL-10 or CX3CR1. NAR disrupted this axis by suppressing VEGFC in hepatocytes. CONCLUSION: Hepatocyte-derived VEGFC is a key contributor to NASH-related liver fibrosis, functioning by regulating macrophage migration and phenotypic switch. The hepatoprotective effect of NAR is partially mediated through the inhibition of the VEGFC-mediated hepatocyte-macrophage regulatory axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlavanonesNon-alcoholic Fatty Liver DiseaseLiver CirrhosisHepatocytesMacrophagesAnimalsDiet, High-FatMaleMiceHumansMice, Inbred C57BLMice, KnockoutDisease Models, AnimalLiver

Stichwörter der Autor:innen

Hepatic fibrosisLy6C(high)MacrophageNASHNaringinPhenotypic switchVEGFC

Substanzen

Flavanonesnaringin

Autor:innen und Institutionen

  • The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, China.
  • The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, China; School of Basic Medical Sciences, Zhejiang Chinese Medical University, Han…
  • The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, China; Zhejiang Hospital (Affiliated Zhejiang Hospital, Zhejiang University Schoo…
  • Zhejiang Hospital (Affiliated Zhejiang Hospital, Zhejiang University School of Medicine), Hangzhou, Zhejiang 310007, China; Key Laboratory of Integrative Chinese and Western Medicine for the Diagnosis and Treatment of C…
  • The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, China. Electronic address: zhiych123@163.com.

Förderung

  • Zhejiang Chinese Medical University
  • National Natural Science Foundation of China
  • Basic Public Welfare Research Program of Zhejiang Province

Zitieren

APA

Li, J., Nie, A., Li, X., Chen, Z., Xu, K., Yan, J., Yao, K., Lin, X., Mao, W., Chen, Z., & Hong, W. (2026). Inhibiting VEGFC - mediated hepatocyte - macrophage regulatory axis contributes to protective effects of naringin against high - fat diet - induced hepatic fibrosis. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157682

Vancouver

Li J, Nie A, Li X, Chen Z, Xu K, Yan J, et al. Inhibiting VEGFC - mediated hepatocyte - macrophage regulatory axis contributes to protective effects of naringin against high - fat diet - induced hepatic fibrosis. Phytomedicine. 2026. doi:10.1016/j.phymed.2025.157682

BibTeX
@article{Li2026,
  author = {Li, Jingya and Nie, Ao and Li, Xinyi and Chen, Zheng and Xu, Kai and Yan, Junbin and Yao, Kannan and Lin, Xiaojie and Mao, Wei and Chen, Zhiyun and Hong, Wei},
  title = {Inhibiting VEGFC - mediated hepatocyte - macrophage regulatory axis contributes to protective effects of naringin against high - fat diet - induced hepatic fibrosis},
  journal = {Phytomedicine},
  year = {2026},
  doi = {10.1016/j.phymed.2025.157682}
}
Kostenlos starten →